Patrick Daly

DocwireNews

Use of momelotinib (MMB) appears to be more effective than danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients, according to a study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.In this study, researchers led by Ruben A. Mesa and colleagues assessed 130 patients with primary or post-ET/PV MF, DIPSS high risk, Int-2, or Int-1, MF Symptom Assessment Form Total Symptom Score (MFSAF TSS) &ge;10, Hgb &lt;10 g/dL, prior JAKi for &ge;90 days, or &ge;28 days if RBC transfusions &ge;4 units in 8 weeks or Gr 3/4 thrombocytopenia, anemia, or hematoma; palpable spleen &ge;5 cm, the researchers noted.The key outcome measure was defined as TSS response (&ge;50% reduction from baseline [BL]) rate at week 24. Secondary endpoints were specified as RBC transfusion independence (TI) rate, splenic response rate (SRR; &ge;25% reduction in volume from BL), change from BL in TSS, SRR (&ge;35% reduction from BL) and rate of zero transfusions since BL.The researchers showed that all primary and key secondary endpoints were met with respect to comparing MMB versus DAN on key symptom, anemia, and spleen volume endpoints at 24 weeks. They concluded that: &ldquo;In symptomatic and anemic MF pts, MMB was superior to DAN for symptom responses, transfusion requirements, and spleen responses with comparable safety and favorable survival. MMB may address a critical unmet need, particularly in MF pts with anemia.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Results from the MOMENTUM Study

ASCO 2022

Use of momelotinib (MMB) appears to be more effective than danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients, according to a study presented at the 2022 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe